Physician profile
James Song
NPI 1679662217
$9,062.10
in general payments reported to CMS, 2019-2025
39 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $504 · 2021: $1,457 · 2022: $1,154 · 2023: $1,501 · 2024: $1,662 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,493 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,492.59 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,518.86 | 2019-2024 | Xarelto |
| Gilead Sciences, INC. | $870.90 | 2020-2025 | Vemlidy |
| Amgen INC. | $734.72 | 2023-2025 | Evenity, Otezla, Otezla |
| Abbvie INC. | $654.20 | 2019-2025 | Creon, Dalvance, Teflaro |
| Lilly USA, LLC | $538.62 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $507.40 | 2019-2024 | |
| Medtronic, INC. | $500.76 | 2022-2024 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $389.56 | 2022-2025 | |
| Astellas Pharma US INC | $344.96 | 2019-2021 | |
| Pfizer INC. | $335.23 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.94 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $225.86 | 2024 | Voquezna |
| Dexcom, INC. | $218.63 | 2021-2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $214.29 | 2022-2024 | Livalo, Seglentis |
| Astrazeneca Pharmaceuticals LP | $199.56 | 2023-2025 | Airsupra, Farxiga, Breztri |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.